Skip to main content

The Wistar Institute

|

Synthetic DNA Vaccine Against Ebola Virus Shows Potent and Long-term Efficacy in Preclinical Studies

PHILADELPHIA — (October 10, 2018) — A novel synthetic DNA vaccine developed based on technology pioneered by scientists at The Wistar Institute Vaccine & Immunotherapy Center offers complete protection from Zaire Ebolavirus (EBOV) infection in…
|

Mechanism of Resistance to Novel Targeted Therapy for Ovarian Cancer Identified

PHILADELPHIA — (Oct. 8, 2018) — Scientists at The Wistar Institute have unraveled a mechanism of resistance to EZH2 inhibitors in ovarian cancers with mutations in the ARID1A gene. The study, published in Nature Communications, suggests that inhib…
|

Engineered Synthetic DNA-Encoded Checkpoint Inhibitor Antibodies Advance the Field of Cancer Immunotherapy

PHILADELPHIA — (Oct. 4, 2018) — Wistar scientists and collaborators demonstrate for the first time that through engineering constructs, they can express DNA-encoded monoclonal antibodies (DMAbs) targeting CTLA-4, an important cancer checkpoint mol…
|

Age-related Changes in Skin Structure and Lymphatic System Permeability Promote Melanoma Metastasis

PHILADELPHIA — (Oct. 2, 2018) — Changes in the structure of the skin and the lymphatic system that occur with the natural aging process create permissive conditions for melanoma metastasis, according to two studies by The Wistar Institute. These c…
|

Targeting Multiple Members of a Family of Tumor Antigens with a Synthetic DNA Vaccine Shows Promise for Cancer Immunotherapy

PHILADELPHIA — (Sept. 27, 2018) — Scientists at The Wistar Institute have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in seve…
|

Virion Therapeutics, LLC Raises $5 Million to Develop Checkpoint Inhibitor Powered Vaccine Therapies for Treatment of Virally Induced Infectious Diseases & Cancers

PHILADELPHIA — (Sept. 26, 2018) — A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies for the treatment of chronic viral-associated cancers and viral…
|

Synthetic DNA Vaccine Effective Against Influenza A Virus Subtype That Is Responsible for More Severe Influenza Seasons

PHILADELPHIA — (Sept. 6, 2018) — Currently available vaccines for the prevention of seasonal influenza virus infection have limited ability to induce immunity against diverse H3N2 viruses, an influenza A subtype that has led to high morbidity and …
|

Enhancing the Efficacy of Immune Checkpoint Inhibitor Therapy Using a Novel Treatment Combination

PHILADELPHIA — (Sept. 5, 2018) — A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically greater antitumor activity than either inhibitor alone, according to research from The Wis…
|

The Wolf Administration Highlights Wistar’s Two Workforce Development Programs During Graduation Award Ceremony

PHILADELPHIA — (August 2, 2018) — The Wistar Institute announces that the Pennsylvania Department of Labor & Industry Secretary Jerry Oleksiak will address graduates from The Wistar Institute’s Biomedical Research Technician (BRT) Apprenticesh…
|

Meet Wistar’s First Medicinal Chemist

In February, Joseph Salvino, Ph.D., joined The Wistar Institute as professor in the Molecular and Cellular Oncogenesis Program and Scientific Director of the Institute’s Molecular Screening Facility. Salvino focuses on drug discovery and developme…